Management of Refractory Agitation in Elderly Hospice Patients

Dosing Strategy for Elderly Patients

• The National Comprehensive Cancer Network recommends quetiapine 50-100 mg PO/SL twice daily for delirium-associated agitation, with doses titrated upward for refractory agitation 2, 3
• Maximum effective doses for agitation in palliative care contexts typically range 200-400 mg/day, as suggested by the American Family Physician and the National Comprehensive Cancer Network 1, 2

Evidence for Quetiapine in Agitation Management

• The National Comprehensive Cancer Network guidelines support quetiapine for severe agitation, preferring it over typical antipsychotics in elderly patients due to lower risk of extrapyramidal symptoms 1, 2, 3
• Quetiapine is effective for delirium-associated agitation, with recommended doses of 50-100 mg PO/SL twice daily 2, 3

Critical Safety Considerations in Hospice Elderly Patients

• Paradoxical agitation can occur with sedatives in elderly patients, and excessive sedation may interfere with quality of life and patient-family interaction 4, 5
• The Annals of Oncology warns of the risk of orthostatic hypotension and excessive sedation in elderly patients, necessitating cautious titration and monitoring 4, 5

Alternative or Adjunctive Approaches if Quetiapine Fails

• The National Comprehensive Cancer Network recommends adding a benzodiazepine for breakthrough agitation, such as midazolam or lorazepam, in patients with refractory agitation despite high-dose quetiapine 2, 3, 4
• Alternative neuroleptics, such as levomepromazine or chlorpromazine, can be considered for delirium with agitation, but with caution due to the risk of hypotension and other adverse effects 2, 4, 5

Common Pitfalls to Avoid

• Typical antipsychotics should not be used first-line due to the risk of tardive dyskinesia, as warned by the American Family Physician 1
• Benzodiazepines should not be added as initial treatment without adequate neuroleptic coverage, as they can worsen delirium and cause paradoxical agitation, according to the Annals of Oncology and the National Comprehensive Cancer Network 2, 4

Monitoring During Titration

• The Annals of Oncology and the National Comprehensive Cancer Network recommend assessing blood pressure, level of sedation, degree of agitation, and signs of delirium at each dose adjustment, as well as reassessing goals of care regularly 2, 3, 4, 5